Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Sosei Group ( (JP:4565) ) has shared an update.
Nxera Pharma reported increased revenues in the first half of 2025, driven by sales of PIVLAZ® and QUVIVIQ® in Japan and progress in partnered programs. The company achieved significant milestones, including a Phase 3 trial for NBI-‘568 and the launch of a proprietary pipeline targeting obesity and metabolic disorders. Financially, Nxera saw a rise in revenue and R&D expenses, while operating losses decreased, indicating strategic investments in their pipeline and collaborations.
The most recent analyst rating on (JP:4565) stock is a Buy with a Yen2000.00 price target. To see the full list of analyst forecasts on Sosei Group stock, see the JP:4565 Stock Forecast page.
More about Sosei Group
Nxera Pharma is a pharmaceutical company operating in the biotech industry, focusing on developing treatments for obesity, metabolic disorders, neurology, neuropsychiatry, immunology, and inflammation. Their primary products include PIVLAZ® and QUVIVIQ®, marketed in Japan, and they leverage their NxWave™ platform for drug development.
Average Trading Volume: 741,862
Technical Sentiment Signal: Sell
Current Market Cap: Yen85.25B
For a thorough assessment of 4565 stock, go to TipRanks’ Stock Analysis page.